Showing results (681-690 of 2,106) with videos related to
Sort By:
Pageof 211
CNS Drugs|June 14, 2017
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying DrugsPeter Joseph JongenCNS Drugs|June 18, 2017
Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year Bi-National Pharmacovigilance Study of Serious or Fatal 'Slow Gut' Reactions, and Comparison with International Drug Safety AdviceSusanna Every-Palmer, Pete M EllisCNS Drugs|April 6, 2018
Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health ClaimsFang-Ju Lin, Hung-Wei Lin, Yunn-Fang HoCNS Drugs|April 7, 2018
Pharmacogenetics of Opioid Use Disorder TreatmentRichard C Crist, Toni-Kim Clarke, Wade H BerrettiniCNS Drugs|April 12, 2018
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's DiseaseLawrence W Elmer, Jorge L Juncos, Carlos Singer, et al.CNS Drugs|April 12, 2018
The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused ReviewPer Damkier, Poul VidebechCNS Drugs|December 5, 2009
Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective studyStefano Pallanti, Silvia Bernardi, Sarah Antonini, et al.CNS Drugs|January 22, 2010
Progress and promise of attention-deficit hyperactivity disorder pharmacogeneticsTanya E Froehlich, James J McGough, Mark A SteinCNS Drugs|August 24, 2016
Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled TrialsKim S J Lao, Ying He, Ian C K Wong, et al.Pageof 211